comparemela.com

Latest Breaking News On - தலைமை முதலீடு மேலாளர் - Page 1 : comparemela.com

Huma raises $130 million financing to scale its digital health platform for better care and research

LONDON and NEW YORK  , May 12, 2021 /PRNewswire/  Huma Therapeutics Limited today announces the completion of its latest funding round with financing of approximately $130 million. The investment will scale Huma s modular platform which can power digital hospitals at home nationally, and support the pharmaceutical and research industries to run the largest ever decentralized clinical trials. Huma s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research. Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV , Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.

Huma raises $130 million to finance its digital health platform – PCR

Huma raises $130 million to finance its digital health platform 5 hours ago Huma Therapeutics Limited thas raised approximately $130 million to scale its modular platform which can power digital ‘hospitals at home’ nationally, and support the pharmaceutical and research industries to run the largest ever decentralised clinical trials. Huma’s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research. Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.

Analytical Flavor Systems Proves: Gastrograph AI Can Predict Consumer Preferences in a Fraction of the Time of Traditional Consumer Research

Share this article Share this article NEW YORK, March 17, 2021 /PRNewswire/  Analytical Flavor Systems (AFS), the company behind Gastrograph AI, an AI platform that models human sensory perception of flavor, aroma, and texture to predict consumer preferences of food and beverage products, today released the results of a new blind research study proving that Gastrograph AI can far more accurately and quickly predict food and beverage perceptions and preferences among different demographic groups than central location testing (CLT). The company also announced significant momentum, including increased commercial adoption and funding from Sony Innovation Fund and BASF Venture Capital. The research, conducted in collaboration with Ajinomoto Co., Inc., a company specializing in amino acid and currently promoting digital transformation in R&D, is the first publicly available validation study of Gastrograph s AI platform. Ajinomoto, a major player in the food industry, designed the blin

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.